BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes
13 avr. 2023 14h03 HE | BioAegis Therapeutics
Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes. Low levels of gelsolin identified in individuals with type 2 diabetes...
XOMA royalty-2c.png
XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies
15 sept. 2016 19h26 HE | XOMA Ltd.
Results Demonstrate XOMA 358 Mechanism-of-Action in Rare Endocrine ConditionsCompany Plans to Advance XOMA 358 to Multi-dose Phase 2b Studies BERKELEY, Calif., Sept. 15, 2016 (GLOBE...
XOMA royalty-2c.png
XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016
06 sept. 2016 09h00 HE | XOMA Ltd.
BERKELEY, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it will host a webcast and...
Xeris Pharmaceuticals Awarded Phase II Funding of NIH Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas
17 avr. 2013 11h39 HE | Xeris Pharmaceuticals, Inc.
Austin, TX, April 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, pharmaceutical company developing patient-friendly injectable treatments for diabetes and other...